PEG + E is safe and highly effective in the management of childhood constipation. It allows a single orally administered laxative to be used for disimpaction without recourse to invasive interventions. It is significantly more effective than lactulose as maintenance therapy, both in efficacy in treating constipation and efficacy in preventing the recurrence of faecal impaction.

A double-blind, controlled, clinical trial of spironolactone (Aldactone-A), 50 mg. b.d., showed this to be better than a placebo for the short-term treatment of benign prostatic hypertrophy, although the advantage was not maintained over a longer period of time. There was considerable response to the placebo and the importance of comparative trials with objective measurements is discussed.

No abstract